Brain cortical assessment by MRI in fetuses with left congenital diaphragmatic hernia Brain development in left congenital diaphragmatic hernia

OBJECTIVE

To evaluate fetal brain development using MRI (magnetic resonance imaging) in CDH (congenital diaphragmatic hernia).

METHODS

52 isolated left CDH and 104 control fetuses were imaged using MRI. Brain morphometry (Biparietal diameter - BPD, brain fronto-occipital diameter - BFOD, third ventricle, posterior ventricles, transcerebellar diameter - TCD, anteroposterior and craniocaudal cerebellar vermis diameter - AP and CC) and cortical structures (bilateral cingulate fissure - CF, insular fissure - IF, insular depth - ID) were compared with controls using Mann-Whitney test .

RESULTS

Median gestational age at MRI was comparable (p=0.95), as well as was the median biparietal diameter (p=0.737). Among morphometric parameters only the brain fronto-occipital diameter was significantly smaller in CDH (p= 0.001) and the third ventricle was significantly greater in CDH (<0.0001). Among cortical structures, the cingulate and insular fissure were significantly deeper in CDH fetuses (p<0.0001), as the insular depth ID was smaller in CDH (p< 0.03).

CONCLUSIONS

CDH fetuses have a smaller fronto-occipitaldiameter, reduced insular depth, and deeper cingulate and insular fissure, and greater third ventricle width as compared to controls. These findings suggest that left CDH may have an impact on fetal brain development with an overall reduction of brain volume. This article is protected by copyright. All rights reserved.

Accuracy of Fetal Biacromial Diameter and Derived Ultrasonographic Parameters to Predict Shoulder Dystocia: A Prospective Observational Study

Background and Objectives: Shoulder dystocia (ShD) is one of most dangerous obstetric complication. The objective of this study was to determine if the ultrasonographic fetal biacromial diameter (BA) and derived parameters could predict ShD in uncomplicated term pregnancies. Materials and Methods: We conducted a prospective observational study in a tertiary care university hospital from March 2021 to February 2022. We included all full-term pregnancies accepted for delivery that received an accurate ultrasonography (USG) scan before delivery. USG biometry and estimated fetal weight (EFW) were collected. Therefore, we evaluated the diameter of the mid-arm, the transverse thoracic diameter (TTD) and the biacromial diameter (BA). BA was estimated using Youssef’s formula: TTD + 2 mid-arm diameters. The primary outcome was the evaluation of BA and its related parameters (BA/biparietal diameter (BPD), BA/head circumference (HC) and BA–BPD in fetuses with ShD versus fetuses without ShD. Diagnostic accuracy for ShD of BA, BA/BPD, BA/HC and BA–BPD was evaluated using receiver operator curve (ROC) analysis. Results: 90 women were included in the analysis, four of these had ShD and required extra maneuvers after head delivery. BA was increased in fetuses with ShD (150.4 cm; 95% CI 133.2 cm to 167.6 cm) compared to no-ShD (133.5 cm; 95% CI 130.1 cm to 137.0 cm; p = 0.04). Significant differences were also found between ShD and no-ShD groups for BA/BPD (1.66 (95% CI 1.46 to 1.86) vs. 1.44 (95% CI 1.41 to 1.48); p = 0.04), BA/HC (0.45 (95% CI 0.40 to 0.49) vs. 0.39 (95% CI 0.38 to 0.40); p = 0.01), BA–BPD (60.0 mm (95% CI 42.4 to 77.6 cm) vs. 41.4 (95% CI 38.2 to 44.6); p = 0.03), respectively. ROC analysis showed an overall good accuracy for ShD, with an AUC of 0.821 (p = 0.001) for BA alone and 0.881 (p = 0.001), 0.857 (p = 0.016) and 0.867 (p = 0.013) for BA/BPD, BA–BPD and BA/HC, respectively. Conclusions: BA alone, as well as BA/BPD, BA/HC and BA–BPD might be useful predictors of ShD in uncomplicated term pregnancies. However, such evidence needs extensive confirmation by means of additional studies with large sample sizes, especially in case of pregnancies at high risk for ShD (i.e., gestational diabetes).

Update of Robotic Surgery in Benign Gynecological Pathology: Systematic Review

Background and Objectives: Since the Food and Drug Administration's (FDA) approval in 2005, the application of robotic surgery (RS) in gynecology has been adopted all over the world. This study aimed to provide an update on RS in benign gynecological pathology by reporting the scientific recommendations and high-value scientific literature available to date. Materials and Methods: A systematic review of the literature was performed. Prospective randomized clinical trials (RCT) and large retrospective trials were included in the present review. Results: Twenty-two studies were considered eligible for the review: eight studies regarding robotic myomectomy, five studies on robotic hysterectomy, five studies about RS in endometriosis treatment, and four studies on robotic pelvic organ prolapse (POP) treatment. Overall, 12 RCT and 10 retrospective studies were included in the analysis. In total 269,728 patients were enrolled, 1721 in the myomectomy group, 265,100 in the hysterectomy group, 1527 in the endometriosis surgical treatment group, and 1380 patients received treatment for POP. Conclusions: Currently, a minimally invasive approach is suggested in benign gynecological pathologies. According to the available evidence, RS has comparable clinical outcomes compared to laparoscopy (LPS). RS allowed a growing number of patients to gain access to MIS and benefit from a minimally invasive treatment, due to a flattened learning curve and enhanced dexterity and visualization.

Quality of Life, Psychological Wellbeing, and Sexuality in Women with Urinary Incontinence—Where Are We Now: A Narrative Review

Urinary incontinence (UI) is a very common condition, negatively affecting social, occupational, domestic, and psychophysical wellbeing. In particular, a peculiar and detrimental effect of UI has been described concerning sexual function. However, the impact of UI on quality of life is not fully understood yet, and further investigation into this issue is warranted. With this narrative review, we aimed to report the current evidence from recent literature regarding the quality of life and psychological wellbeing in patients with urinary incontinence, with a special focus on sexual function and its evolution after UI treatment. There is strong evidence that urinary incontinence—in its different forms, including stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and coital urinary incontinence—negatively affects female sexual function. Treatments aimed to cure urinary incontinence—including pelvic floor muscles training, medications, and surgery—seem to improve quality of life by recovering, at least in part, sexual function. In conclusion, there is a substantial association between involuntary urinary loss and sex life quality. However, few studies are available and more evidence is needed before consistent conclusions can be made.

FRI0479 REWIRED CELL ENERGY METABOLISM IN A NOVEL KRAS-MUTATED HISTIOCYTOSIS CHARACTERIZED BY SEVERE SYNOVITIS

Background:

Histiocytoses are disorders characterized by tissue infiltration by macrophages, dendritic cells, or monocyte-derived cells. These diseases are classified in five groups based on histologic, clinical, and molecular features: Langerhans-related, cutaneous/mucocutaneous and malignant histiocytoses, Rosai-Dorfman disease, and hemophagocytic lymphohistiocytosis (1). Langerhans-related histiocytoses comprise Langerhans cell histiocytosis and Erdheim-Chester disease, both inflammatory myeloid-driven diseases characterized by clonal activating mutations along the MAPK or related pathways, most commonlyBRAFV600E, and by severe tissue and systemic inflammation (2). Here, we describe and characterize a novel, related histiocytosis chiefly manifested with severe synovial involvement.

Objectives:

Here, we describe a novel histiocytosis whose histologic and clinical picture (severe synovial involvement, systemic inflammation, skin lesions, and diabetes insipidus) differed from known histiocytic disorder. In addition, we performed molecular studies aimed at identifying causative activating mutations. Finally, by means of a dynamic 3D tissue culture system we characterized immune-metabolic mechanisms underlying disease pathogenesis and clinical response to treatment.

Methods:

The mutational status of oncogenes was determined with a mass spectrometry multiplexed genotyping approach (PentaPanel). Biospy samples were cultured in RCCSTM bioreactor (Synthecon) in the presence/absence of a MEK inhibitor (GSK1120212, 1nM), and then either processed for immunohistochemical analyses, or lysed for western blot analysis. Culture supernatants were collected for cytokine, chemokine and metabolome determination. The Bio-Plex Multiple-Cytokine Assay (Bio-Rad) and the Ella assay (ProteinSimple) were used to determine cytokine concentrations in supernatants and serum, respectively. Metabolomic studies were performed as described (3).

Results:

We identified a causative mutation in the proto-oncogeneKRAS(KRASG12D, not previously reported in related histiocytoses). In addition, 3D culture studies of patient’s biopsies revealed KRAS-driven signaling, phenotypic, and immunometabolic features. These included constitutive ERK and AKT phosphorylation, up-regulated glucose metabolism with glycolysis and TCA cycle activation, and deregulated release of pro-inflammatory cytokines IL-1β, IL-6 and TNFα. All these features reverted upon pharmacologic inhibition of the MAPK pathway. Characterization of this novel condition instructed effective treatment of the patient with the MEK inhibitor cobimetinib.

Conclusion:

Genetic, clinical, and histopathology features differentiate this condition from known histiocytic disorders. Mechanistically,KRASG12Dcauses constitutive activation of the MAPK pathway in macrophages, which results in maladaptive changes in cell energy metabolism sustaining rampant production of pro-inflammatory cytokines. Besides instructing effective treatment of this patient, these studies revealed metabolic rewiring as key to pathologic inflammatory activation of macrophages in human disease.

References:

[1]Emile JF, et al. Revised classification of histiocytoses. Blood. 2016

[2]Cavalli G, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease. Ann Rheum Dis. 2013

[3]Cavalli G, et al. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A. 2017

Disclosure of Interests:

Giulio Cavalli Consultant of: SOBI, Pfizer, Sanofi, Novartis, Paid instructor for: SOBI, Novartis, Speakers bureau: SOBI, Novartis, Giacomo De Luca Speakers bureau: SOBI, Novartis, Celgene, Pfizer, MSD, Riccardo Biavasco Employee of: Bluebird, Travis Nemkov: None declared, Angelo D’Alessandro: None declared, Rob Arts: None declared, Antonello Villa: None declared, Daniela Belloni: None declared, Greta Grassini: None declared, Giulia Cangi: None declared, Claudio Doglioni: None declared, Elisabetta Ferrero: None declared, Marina Ferrarini: None declared, Lorenzo Dagna: None declared

On the effect of alkaline pH and cofactor availability in the conformational and oligomeric state of Escherichia coli glutamate decarboxylase

Escherichia coli glutamate decarboxylase (EcGad) is a homohexameric pyridoxal 5'-phosphate (PLP)-dependent enzyme. It is the structural component of the major acid resistance system that protects E. coli from strong acid stress (pH < 3), typically encountered in the mammalian gastrointestinal tract. In fact EcGad consumes one proton/catalytic cycle while yielding γ-aminobutyrate and carbon dioxide from the decarboxylation of l-glutamate. Two isoforms of Gad occur in E. coli (GadA and GadB) that are 99% identical in sequence. GadB is the most intensively investigated. Prompted by the observation that some transcriptomic and proteomic studies show EcGad to be expressed in conditions far from acidic, we investigated the structural organization of EcGadB in solution in the pH range 7.5-8.6. Small angle X-ray scattering, combined with size exclusion chromatography, and analytical ultracentrifugation analysis show that the compact and entangled EcGadB hexameric structure undergoes dissociation into dimers as pH alkalinizes. When PLP is not present, the dimeric species is the most abundant in solution, though evidence for the occurrence of a likely tetrameric species was also obtained. Trp fluorescence emission spectra as well as limited proteolysis studies suggest that PLP plays a key role in the acquisition of a folding necessary for the canonical catalytic activity.

Ranitidine and somatostatin. Their effects on bleeding from the upper gastrointestinal tract

In a randomized, double-blind placebo-controlled clinical trial, the effect of ranitidine was compared with the effect of somatostatin in the control of massive gastrointestinal tract bleeding. Ninety-six patients completed the study. Rates of continuing bleeding and death, incidence of surgery, and blood transfusion requirements were not significantly different in the three treatment groups. Eighteen of the 96 patients presented with a visible vessel at endoscopy. In this group the percent of patients with continuing bleeding, mean transfusion requirements, and mortality were significantly higher than in patients without a visible vessel. Seven patients with a visible vessel underwent surgery and six survived; 11 patients underwent conservative measures and eight died. Ranitidine and somatostatin do not seem to alter the clinical course of patients with upper gastrointestinal tract hemorrhage.

Operative morbidity after shunt surgery for portal hypertension

The operative morbidity observed in a consecutive series of 286 patients who underwent shunt surgery for portal hypertension is reported. 149 patients out of 286 (52.1%) had a postoperative complication, which required reoperation in 11 cases (5 intestinal perforations, 2 bleeding peptic ulcers, 1 eventratio, 1 cholestasis, 1 acute pancreatitis, 1 strangulated hernia). 42 patients out of the 149 with complications died of the complication (operative mortality 14.6%). Operative morbidity and mortality appeared higher in patients operated as emergencies. Whereas elective shunts gave better results. The problem involved in preventing and treating the serious complications following shunt surgery for portal hypertension are discussed.